Related Experiment Video
Updated: Mar 22, 2026
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Prediction and preliminary screening of HLA-A*0201-restricted epitope peptides of human GPC3
Abstract:
In response to the limited therapeutic option for hepatocellular carcinoma (HCC), immunotherapy as a promising approach points out a new direction to the cure of tumours through specific recognition and elimination of tumour cells by the immunity-enhanced autologous immunocytes of patients. Few effective tumour antigens, however, are alternative in addition to alpha fetoprotein or tumour cell lysates. Recent studies have demonstrated that glypican-3 (GPC3) is not only a promising diagnostic marker, but also ideal therapeutic target to HCC. In this study, potential HLA-A*0201 GPC3 peptides were screened with three epitope prediction software, the binding affinity of 13 predicted epitopes with high scores was determined by T2 cells binding assay and four optimal epitopes were identified. This is the first study in which the optimal HLA-A*0201 GPC3 epitopes were screened from a large number of candidates predicted by three software. The optimized HLA-A*0201 GPC3 peptides will provide new epitope candidates for HCC immunotherapy.
Insights
Hepatocellular carcinoma (HCC) immunotherapy shows promise. Researchers identified four optimal HLA-A*0201 GPC3 peptides, offering new targets for HCC treatment and enhancing immunotherapy options.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) has limited therapeutic options.
- Immunotherapy offers a promising new direction for cancer treatment.
- Glypican-3 (GPC3) is an emerging therapeutic target for HCC.
Purpose of the Study:
- To identify novel HLA-A*0201 GPC3 peptides for HCC immunotherapy.
- To screen and validate potential GPC3 epitopes for therapeutic use.
Main Methods:
- Utilized three epitope prediction software to screen potential HLA-A*0201 GPC3 peptides.
- Determined the binding affinity of 13 high-scoring predicted epitopes using T2 cells binding assay.
- Identified four optimal GPC3 epitopes based on binding affinity.
Main Results:
- Successfully screened a large number of candidate HLA-A*0201 GPC3 epitopes.
- Identified four optimal GPC3 peptides with high binding affinity.
- This study represents the first comprehensive screening of optimal HLA-A*0201 GPC3 epitopes using multiple prediction tools.
Conclusions:
- The identified optimal HLA-A*0201 GPC3 peptides are promising candidates for HCC immunotherapy.
- These findings contribute to the development of novel therapeutic strategies for hepatocellular carcinoma.
- The study provides a foundation for further research into GPC3-based cancer vaccines and T-cell therapies.
